Posted on 05/06/2023 1:49:36 PM PDT by bitt
A recent phase three study conducted by Eli Lilly examined the safety and efficacy of the study drug donanemab in participants with early Alzheimer's disease (AD).
The pharmaceutical company Eli Lilly announced in a press release on May 3, 2023, that a clinical trial of the experimental Alzheimer's drug, donanemab, showed it could significantly slow the progress of cognitive decline, allowing patients increased independence.
The drugmaker's announcement revealed that the drug succeeded in halting early AD progression in nearly half of the participants, slowing cognitive decline rates by 35% compared to control participants.
Donanemab is an antibody that targets protein aggregates, known as amyloid beta proteins, which are the causative agents of brain plaques. Despite the direct causes of Alzheimer's being unknown, brain plaques have been thought to slow brain function and thus advance cognitive decline.
If the therapy were approved by the Food and Drug Administration (FDA), it would become the third Alzheimer’s drug to enter the market in the past three years. Safety concerns remain despite the promising trial results, with at least two participants experiencing fatal brain swelling.
(Excerpt) Read more at news-medical.net ...
p
Better alternative to any drugs is regular mildly aerobic exercise. I am living example at age 83.
I don’t believe anything these lying companies say.
Yeh, it’s called vitamin D3
How much are they charging?
Congrats!
“Better alternative to any drugs is regular mildly aerobic exercise. I am living example at age 83.”
My very fit neighbor died of temporal lobe dementia. A dead example at age 70 of it making no difference.
Yes, how expensive is this?
Asking for a friend...
How many boosters?
“Don’t believe anything, not one thing put out by a pharmaceutical company. Just don’t believe it. You start from there.”
Catherine DeAngelis, Editor in Chief, Journal of the American Medical Association
Old fatass couch potatoes unite!
And make a potato salad :)
The decline was marginal when looked at the entire universe of Alzheimer’s patients. The drug was marginally effective against a control group. The press release makes it sound like an amazing breakthrough. It’s not.
Don’t get me wrong, progress is good. But PR departments toss around percentages that are not even close to their claims.
It’s like heart drugs that reduce heart attack risk by 20%. What they do t tell you is that your average risk of a heart attack is less than 1% per year. Dropping it to .8% is not meaningful to most people.
Vascular dementia is going to happen if you exercise or not. Exercise is great for a lot of reasons. But vascular dementia has more to do with body chemistry.
My brother’s was told that it was about $9000 per month. I hate the greed of pharma!
My brother’s was told that it was about $9000 per month. I hate the greed of pharma!
I just wrote a computer program to monitor my bond holdings and alert me when to sell or switch. Several hundred lines long code, written in dBase-5. Regular exercise keeps my heart and lungs running normal, and keeps arteries from clogging up. Come a long way from age 55 when I had chest pains, irregular hear beats, racing heart. Now at age 83 every year the EKG is normal. I made no change in diet. Only change is adding exercise 4 days every week.
My LDL is higher than normal. But I refuse to take statins. I don’t even get out of breath climbing stairs to 3rd floor of my condo building. And still writing computer programs to monitor my investments. Not even close to dementia at age 83. Regular Exercise is my key to staying physically and mentally healthy. Not taking any prescriptions except minimum dose Lisinopril 10mg.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.